Abernethy D R, Egan J M, Dickinson T H, Carrum G
Division of Clinical Pharmacology, Brown University, Providence, Rhode Island.
J Pharmacol Exp Ther. 1988 Mar;244(3):994-9.
Antipyrine and theophylline disposition was studied in healthy volunteer subjects in the control state while the subjects were taking verapamil (120 mg) orally four times daily or diltiazem (120 mg) orally three times daily. Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume. Fractional clearances of urinary antipyrine metabolites 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, norantipyrine and unchanged antipyrine were differentially changed by verapamil and diltiazem treatment. With verapamil treatment, 4-hydroxyantipyrine and norantipyrine fractional clearances were markedly decreased, with 3-hydroxymethylantipyrine slightly decreased and antipyrine unchanged. With diltiazem treatment, 3-hydroxymethylantipyrine was decreased, with no significant change in 4-hydroxyantipyrine, norantipyrine or antipyrine. Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment. Fractional clearances of urinary theophylline metabolites 3-methylxanthine, 1-methyluricacid, 1,3-dimethyluricacid and unchanged theophylline reflected the differential plasma theophylline clearance. During verapamil treatment, 3-methylxanthine and 1,3-dimethyluricacid fractional clearances were decreased, with no change in 1-methyluricacid or theophylline. During diltiazem treatment, 1,3-dimethyluricacid fractional clearance was slightly decreased, and 3-methylxanthine, 1-methyluricacid and theophylline were unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
在健康志愿者处于对照状态时,研究了安替比林和茶碱的处置情况,这些志愿者每日口服维拉帕米(120毫克)4次或地尔硫䓬(120毫克)3次。维拉帕米和地尔硫䓬治疗均降低了安替比林清除率(维拉帕米,从42.5降至30.1毫升/分钟,P小于0.01;地尔硫䓬,从41.7降至29.9毫升/分钟,P小于0.01),导致安替比林半衰期延长,分布容积无变化。维拉帕米和地尔硫䓬治疗对尿中安替比林代谢物4-羟基安替比林、3-羟甲基安替比林、去甲安替比林和未变化的安替比林的分数清除率有不同影响。维拉帕米治疗时,4-羟基安替比林和去甲安替比林分数清除率显著降低,3-羟甲基安替比林略有降低,安替比林无变化。地尔硫䓬治疗时,3-羟甲基安替比林降低,4-羟基安替比林、去甲安替比林或安替比林无显著变化。维拉帕米治疗(从每分钟57.7降至44.7毫升;P小于0.01)和地尔硫䓬治疗(从每分钟50.2降至49.4毫升;无显著差异)对茶碱清除率的影响不同,维拉帕米治疗期间茶碱半衰期延长,地尔硫䓬治疗期间半衰期无变化,两种治疗对分布容积均无影响。尿中茶碱代谢物3-甲基黄嘌呤、1-甲基尿酸、1,3-二甲基尿酸和未变化的茶碱的分数清除率反映了血浆中茶碱清除率的差异。维拉帕米治疗期间,3-甲基黄嘌呤和1,3-二甲基尿酸分数清除率降低,1-甲基尿酸或茶碱无变化。地尔硫䓬治疗期间,1,3-二甲基尿酸分数清除率略有降低,3-甲基黄嘌呤、1-甲基尿酸和茶碱无变化。(摘要截短至250字)